Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice.
Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1).
A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
